Observational studyMedicine2017
Should Roux-en-Y gastric bypass biliopancreatic limb length be tailored to achieve improved diabetes outcomes?
Observational study in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Pooled it
- Meta-analysis of Long-Term Relapse Rate of Type 2 Diabetes Following Initial Remission After Roux-en-Y Gastric Bypass.Obesity surgery · 2021Pooled it
- Effect of RYGB Limb Lengths on HbA1c in Patients with Obesity and Type 2 Diabetes.Obesity surgery · 2026Trial
- Long Biliopancreatic Limb (BPL) RYGB Versus Short BPL RYGB Post-Suboptimal Initial Clinical Response of SG or Recurrent Weight Gain: A Randomized Controlled Study.Obesity surgery · 2025Trial
- Standard Biliopancreatic Limb (50 cm) Roux-en-Y Gastric Bypass Versus Long Biliopancreatic Limb (100 cm) Roux-en-Y Gastric Bypass in Patients with Body Mass Index 40-50 kg/mObesity surgery · 2022Trial
- Midterm Results from the Dutch Common Channel Trial (DUCATI): Superior Weight Loss Results of the Long Roux Limb Gastric Bypass in Comparison to the Standard Bypass at 3-Year Follow-Up.Obesity surgery · 2021Trial
- Trial
- Efficacy and safety of limb distalization after Roux-en-Y gastric bypass: a retrospective cohort study.Frontiers in surgery · 2026Article
- Robotic hand-sewn vs. laparoscopic linear-stapled Roux-en-Y gastric bypass: a propensity score-matched analysis of primary and conversion cases.Frontiers in surgery · 2026Article
- Mid-term Outcomes in Primary Roux-en-Y Gastric Bypass Procedures with Short or Long Biliopancreatic Limb.Obesity surgery · 2025Article
- Long-Term Outcomes of Single and Dual Anastomosis Duodenal Switch.Obesity surgery · 2025Article
- Total Alimentary Limb Length Is Not Associated with Weight Loss Following Proximal Roux-en-Y Gastric Bypass.Obesity surgery · 2025Observational
- Enhanced Total Weight Loss 2 Years Post-Roux-en-Y Gastric Bypass with Longer Biliopancreatic Limb.Obesity surgery · 2025Article
- The Impact of Early-Stage Chronic Kidney Disease on Weight Loss Outcomes After Gastric Bypass.Obesity surgery · 2023Article
- Individuals with type 2 diabetes have higher density of small intestinal neurotensin-expressing cells.Molecular and cellular biochemistry · 2023Article
- Remission of Type II Diabetes Mellitus after Duodenal Switch: the Contribution of Common Channel Length.Obesity surgery · 2023Article
- Accuracy of prediction models for long-term type 2 diabetes remission after gastric bypass.Acta diabetologica · 2023Article
- Physical properties of food or bile redirection do not contribute to the intestinal adaptations after Roux-en-Y Gastric Bypass in rats.Obesity science & practice · 2023Article
- Article
- Effects of short or long biliopancreatic limb length after laparoscopic Roux-en-Y gastric bypass surgery for obesity: a propensity score-matched analysis.Langenbeck's archives of surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective is to access the role of Roux-en-Y gastric bypass (RYGB) biliopancreatic limb (BPL) length in type 2 diabetes (T2D) outcomes.RYGB is more effective than medical intervention for T2D treatment in obese patients. Despite the scarcity of available data, previous reports suggest that modifications of the RYGB limb lengths could improve the antidiabetic effects of the surgery.A cohort of obese T2D patients (n = 114) were submitted to laparoscopic RYGB, either with a standard BPL (SBPL) (n = 41; BPL 84 ± 2 cm) or long BPL (LBPL) (n = 73; BPL = 200 cm) and routinely monitored for weight loss and diabetic status up to 5 years after surgery.Baseline clinical features in the 2 patient subgroups were similar. After surgery, there was a significant reduction of body mass index (BMI) in both the groups, although the percentage of excess BMI loss (%EBMIL) after 5 years was higher for LBPL (75.50 ± 2.63 LBPL vs 65.90 ± 3.61 SBPL, P = .04). T2D remission rate was also higher (73% vs 55%, P < .05), while disease relapse rate (13.0% vs 32.5%; P < .05) and antidiabetic drug requirement in patients with persistent diabetes were lower after LBPL. Preoperative T2D duration predicted disease remission, but only for SBPL.RYGB with a longer BPL improves %EBMIL, T2D remission, and glycemic control in those with persistent disease, while it decreases diabetes relapse rate over time. The antidiabetic effects of LBPL RYGB also are less influenced by the preoperative disease duration. These data suggest the RYGB procedure could be tailored to improve T2D outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.